Prediction of mild cognitive impairment progression using time-sensitive multimodal biomarkers
Alzheimer’s disease (AD) develops silently for years before symptoms emerge, making early identification of at-risk individuals essential for prevention trials and early intervention. We tested whether combining neurophysiological, imaging, and blood biomarkers improves prediction of progression to mild cognitive impai...